{"id":"proquad","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Injection site reactions (erythema, swelling, tenderness)"},{"rate":"15-20","effect":"Fever"},{"rate":"3-5","effect":"Rash"},{"rate":"3-5","effect":"Varicella-like rash"},{"rate":"<1","effect":"Parotitis"},{"rate":"<1","effect":"Measles-like rash"}]},"_chembl":{"chemblId":"CHEMBL6068357","moleculeType":"Vaccine component"},"_dailymed":{"setId":"73eae9fc-507b-4c9c-883d-63eb2e3cc6f6","title":"PROQUAD (MEASLES, MUMPS, RUBELLA AND VARICELLA VIRUS VACCINE LIVE) INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION [MERCK SHARP & DOHME LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ProQuad contains weakened (attenuated) strains of measles, mumps, rubella, and varicella-zoster viruses. When administered, these live vaccine viruses replicate in the body at a limited level, triggering both humoral and cell-mediated immune responses that generate protective antibodies and cellular immunity against all four diseases without causing the actual diseases.","oneSentence":"ProQuad is a live attenuated combination vaccine that stimulates immune response against measles, mumps, rubella, and varicella viruses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:06.675Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of measles, mumps, rubella, and varicella in children aged 12 months and older"}]},"trialDetails":[{"nctId":"NCT02687763","phase":"EARLY_PHASE1","title":"Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2015-12","conditions":"RENAL INSUFFICIENCY, CHRONIC, LIVER FAILURE, ACUTE, HEART DISEASE","enrollment":5},{"nctId":"NCT00326183","phase":"PHASE4","title":"Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-26","conditions":"Hepatitis A, Measles, Mumps","enrollment":1800},{"nctId":"NCT00578175","phase":"PHASE2","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-20","conditions":"Varicella, Rubella, Mumps","enrollment":1851},{"nctId":"NCT01506193","phase":"PHASE3","title":"Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-02-06","conditions":"Rubella, Varicella, Measles","enrollment":716},{"nctId":"NCT00402831","phase":"PHASE3","title":"ProQuad® Intramuscular vs Subcutaneous","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-06","conditions":"Measles, Mumps, Rubella","enrollment":405},{"nctId":"NCT00969436","phase":"PHASE3","title":"Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-09","conditions":"Varicella, Rubella, Mumps","enrollment":450},{"nctId":"NCT00432042","phase":"PHASE3","title":"Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-12","conditions":"Varicella, Measles, Mumps","enrollment":955},{"nctId":"NCT00566527","phase":"PHASE3","title":"Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-29","conditions":"Measles, Mumps, Rubella","enrollment":1620},{"nctId":"NCT00560755","phase":"PHASE3","title":"Safety Study of ProQuad® rHA in Infants (V221-037)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10-24","conditions":"Measles, Mumps, Rubella","enrollment":3388},{"nctId":"NCT00406211","phase":"PHASE3","title":"Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-07","conditions":"Rubella, Varicella, Mumps","enrollment":398},{"nctId":"NCT00483574","phase":"PHASE3","title":"Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-05","conditions":"Meningococcal Meningitis, Measles, Mumps","enrollment":1378},{"nctId":"NCT00384397","phase":"PHASE3","title":"A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-09","conditions":"Meningococcal Meningitis, Measles, Mumps","enrollment":1128},{"nctId":"NCT00422292","phase":"PHASE3","title":"Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-12","conditions":"Meningococcal Meningitis, Measles, Mumps","enrollment":1664},{"nctId":"NCT02712203","phase":"","title":"MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.","status":"UNKNOWN","sponsor":"CHU de Quebec-Universite Laval","startDate":"2004-07","conditions":"Measles","enrollment":5808},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ProQuad®","genericName":"ProQuad®","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"ProQuad is a live attenuated combination vaccine that stimulates immune response against measles, mumps, rubella, and varicella viruses. Used for Prevention of measles, mumps, rubella, and varicella in children aged 12 months and older.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}